UNICANCER: clinical-trial pipeline
UNICANCER is the sponsor of 220 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 89 are not yet finished and 0 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Trials by phase
| Phase | Trials |
|---|---|
| Phase 2 | 102 |
| Phase 3 | 66 |
| Not applicable | 40 |
| Phase 1/2 | 5 |
| Phase 2/3 | 4 |
| Phase 1 | 3 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 106 |
| Active, not recruiting | 37 |
| Recruiting | 37 |
| Terminated | 18 |
| Not yet recruiting | 15 |
| Withdrawn or not authorised | 4 |
| Suspended or halted | 3 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 217 |
| Nephrology and urology | 34 |
| Gastroenterology and liver | 17 |
| Women's health and obstetrics | 12 |
| Musculoskeletal | 4 |
| Rare and genetic diseases | 4 |
| Dermatology | 3 |
| Metabolic and endocrine (diabetes, obesity) | 3 |
| Haematology | 2 |
| Infectious disease and vaccines | 2 |
| Neurology | 2 |
| Psychiatry and mental health | 1 |
Countries
| Country | Trials |
|---|---|
| France | 212 |
| Belgium | 18 |
| Spain | 15 |
| Italy | 10 |
| United Kingdom | 5 |
| Ireland | 5 |
| Netherlands | 5 |
| Switzerland | 4 |
| Martinique | 4 |
| Sweden | 4 |
| Canada | 2 |
| Germany | 2 |
| Romania | 2 |
| Slovakia | 2 |
| United States | 2 |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05041842 | Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer | Phase 2 | Active, not recruiting | France |
| 2023-505298-34-00 | Pan-MSI-ACSE: Dostarlimab as first-line treatment for patients with dMMR/MSI (non-colorectal/non-endometrial)… | Phase 2 | Recruiting | France |
| NCT06496581 | Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders) | Phase 3 | Recruiting | Belgium, Spain, France, Ireland +2 |
| NCT05617963 | Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Diseas… | Phase 2 | Active, not recruiting | France |
| NCT04757337 | Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcom… | Phase 3 | Recruiting | France |
| NCT02817958 | Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the… | Phase 2 | Active, not recruiting | France |
| NCT06625970 | Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Pati… | Phase 3 | Recruiting | Spain, France, Martinique |
| NCT06078384 | Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage… | Phase 2 | Recruiting | Spain, France |
| NCT03697850 | Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy | Phase 2 | Active, not recruiting | France |
| NCT06276465 | Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metasta… | Phase 3 | Recruiting | Belgium, Spain, France, Ireland |
| NCT05297617 | Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk | Phase 2 | Recruiting | France |
| NCT05476796 | Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With… | Phase 2 | Active, not recruiting | France |
| NCT03643133 | Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients | Phase 2 | Active, not recruiting | France |
| NCT02304809 | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterat… | Phase 2 | Active, not recruiting | France |
| NCT06524583 | Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having… | Phase 2 | Recruiting | Spain, France |
| NCT06245356 | Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With M… | Phase 2 | Recruiting | France |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients i… | Phase 3 | Active, not recruiting | France |
| NCT04181203 | Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy | Phase 3 | Active, not recruiting | France |
| NCT00470223 | Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma | Phase 3 | Active, not recruiting | France |
| NCT01805271 | Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER… | Phase 3 | Active, not recruiting | Belgium, France |
| NCT01442246 | Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrenc… | Phase 3 | Active, not recruiting | France |
| NCT01376752 | Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in Relapse Ovarian Cancer Treatment | Phase 3 | Active, not recruiting | Belgium, Spain, France |
| NCT04158362 | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer | Phase 3 | Active, not recruiting | France |
| NCT06653777 | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumo… | Phase 2 | Recruiting | France |
| NCT06450314 | Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests. | Phase 2 | Recruiting | France |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "UNICANCER clinical trials: 89 open, 70 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/unicancer/, data as of 2026-10-25.